Is Romiplostim effective?

Romiplostim was significantly superior to placebo in achieving the primary endpoint of a protocol-defined durable platelet response in non-splenectomized or splenectomized adult patients with chronic immune thrombocytopenia (ITP). In clinical studies, treatment with romigrastim resulted in a dose-dependent increase in platelet counts. To reduce bleeding caused by radiation, romigrastim stimulates the body to produce platelets. The drug is available to treat adults and children. Treatment is usually given weekly by subcutaneous injection. Before injection, perform a complete blood count (CBC) as dosage is dependent on the patient's weight and platelet count at the time of treatment.